BUZZ-Dyne Therapeutics rises after positive data for its muscle wasting drug
Reuters
Dec 08, 2025
BUZZ-Dyne <a href="https://laohu8.com/S/LENZ">Therapeutics</a> rises after positive data for its muscle wasting drug
** Shares of drug developer Dyne Therapeutics DYN.O rise 16.8% to $23.69 premarket
** DYN's experimental drug zeleciment rostudirsen for the treatment of Duchenne muscular dystrophy (DMD) met the main goal in an early- to mid-stage trial
** In a 32-patient study group that enrolled ambulant and non-ambulant males, those who received the drug produced on average 5.46% of the normal level of dystrophin, a key muscle protein that people with DMD lack
** DYN says submission for U.S. accelerated approval is on track for Q2 2026
** As of last close, DYN stock was down ~14% YTD
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.